Study of a new drug for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with a diagnosis of advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer (stage IIIB/C or IV).
- Your tumor is of a non-mucinous type (like serous, endometrioid, or mixed).
- You are able to receive chemotherapy before surgery (neoadjuvant).
- You agree to provide a tumor sample for biomarker testing (HRD vs HRP).
- You have adequate organ function (bone marrow, kidney, liver) and a good performance status (ECOG 0-2).
- You are not pregnant, not breastfeeding, and willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
This study tests a new drug (BG-C9074) combined with a standard targeted therapy (bevacizumab) for women newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding this new drug can help shrink or control the cancer better than the standard approach alone.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.